Focus: Vor Biopharma is a clinical-stage biopharmaceutical company focused on CAR-T stem cell therapy for hematologic malignancies and autoimmune diseases, headquartered in Cambridge, MA. The company operates in the high-value cell and gene therapy space with multiple Phase 3 programs.
Profile data last refreshed 20m ago · AI intelligence enriched 2mo ago
Cooling — net -11 jobs in 30d
0 added, 11 removed. Slower than typical.
Strong fit for early-career and mid-career professionals seeking deep expertise in cell therapy with meaningful clinical impact, provided you can tolerate binary regulatory risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vor Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vor Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) The Globe and Mail
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes - Seeking Alpha
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes Seeking Alpha
Vor Bio adds Verona Pharma veteran David Zaccardelli to board - Stock Titan
Vor Bio adds Verona Pharma veteran David Zaccardelli to board Stock Titan
Vor Biopharma shifts to autoimmune drug development with $491.5M cash, advancing Phase 3 trials for telitacicept. - pluang.com
Vor Biopharma shifts to autoimmune drug development with $491.5M cash, advancing Phase 3 trials for telitacicept. pluang.com
8-K Filing: Vor Biopharma Inc. (VOR) (CIK 0001817229) — 8-K
8-K
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo